In patients with liver metastases, Kisqali combination therapy cut the risk of death by 47% and 37% in two trials More: New analysis shows survival benefit of Novartis' Kisqali Source: News
read moreEvidence from trials suggests that tumours with NTRK gene fusions shrink in response to larotrectinib More: NICE issues final guidance on NHS use of Bayer's Vitrakvi Source: News
read moreThe group will work on two experimental vaccines and an antiviral More: MSD unveils bid to tackle coronavirus pandemic Source: News
read moreThe drug will be provided to the NHS free of charge by Gilead via the UK’s early access to medicines scheme More: NHS patients to be given experimental coronavirus therapy remdesivir Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals